Skip to main content
NewslettersWatchlist

Biomarin Pharmaceuticals(BMRN-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low66.67
Day High67.44
Open:66.76
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
Barchart
2 'Strong Buy'-Rated Stocks That Could Rally 39% to 48% in 2025
MarketBeat
3 Oversold Stocks with Big RSI Rebound Potential
Yolowire
Junior Biotech Utilizes AI To Shorten Drug Discovery Timelines, Ultimately Saving Lives
Barchart
Stock Index Futures Tread Water as Investors Brace for Fed Minutes and Powell’s Speech
Motley Fool
4 Incomparable Growth Stocks You'll Regret Not Buying in the New Nasdaq Bull Market
Motley Fool
4 Dominant Growth Stocks You'll Regret Not Buying in the New Nasdaq Bull Market
Motley Fool
4 Extraordinary Growth Stocks You'll Regret Not Buying in the New Nasdaq Bull Market
Motley Fool
3 No-Brainer Stocks to Buy With $200 Right Now
Motley Fool
4 Marvelous Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip
Motley Fool
4 Preeminent Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip
Motley Fool
4 Unique Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip
Motley Fool
3 Under-the-Radar Biotech Stocks to Buy in 2023
PR Newswire
BioMarin to Host Third-Quarter 2023 Financial Results Conference Call and Webcast on Wednesday, November 1, at 4:30pm ET
MarketBeat
Are Gene Therapy Stocks The Market's Next Big Winners?
Motley Fool
4 Awe-Inspiring Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip
PR Newswire
BioMarin to Present Data Showing Long-Term Benefit of VOXZOGO® (vosoritide) on Growth in Children with Achondroplasia at 2023 European Society for Paediatric Endocrinology (ESPE) Meeting
PR Newswire
BioMarin Receives Positive CHMP Opinion in Europe to Expand Use of VOXZOGO® (vosoritide) to Treat Children Aged 4 Months and Older with Achondroplasia
PR Newswire
BioMarin to Present Innovative Pipeline at R&D Day on September 12th in New York
PR Newswire
BioMarin to Participate in Three Upcoming Investor Conferences
Motley Fool
4 Preeminent Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip
PR Newswire
BioMarin Announces First Person Treated Commercially with ROCTAVIAN® (valoctocogene roxaparvovec-rvox) for Severe Hemophilia A in Europe
PR Newswire
Levi & Korsinsky LLP notifies shareholders of BMRN, MAXR, SYF, PGEN of pending class action settlements

Profile

BioMarin Pharmaceutical Inc. focuses on the development and commercialization of treatments for serious life-threatening medical conditions, mostly for children. The company's portfolio comprises seven marketed products namely, Aldurazyme, Naglazyme, Kuvan a rare genetic enzyme deficiency disorder), Vimizim , Brineura, Palynziq and Voxzogo. BioMarin has a collaboration agreement with Sanofi's subsidiary Genzyme for Aldurazyme. Genzyme is BioMarin's sole customer for Aldurazyme and is responsible for marketing and selling Aldurazyme to third parties.'The newest drug in BioMarin's portfolio, Voxzogo for treating achondroplasia, the most common form of dwarfism. BioMarin's biologics license application (BLA) for Roctavian/valoctocogene roxaparvovec (valrox), a gene therapy for severe hemophilia A, was given a complete response letter (CRL) by the FDA.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.